Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114387 · ClinicalTrials.gov registry record · Phase 2
VEAPS: Vitamin E Atherosclerosis Prevention Study
A Phase 2 study of Atherosclerosis, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
- 1
- Study location
NCT00114387 is a Phase 2 study of Atherosclerosis that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 353 participants, below the 1,061-participant average among 69 other Atherosclerosis trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00114387, a Phase 2 study of Atherosclerosis, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether vitamin E (DL-alpha-tocopherol) supplementation will reduce the progression of early atherosclerosis in healthy individuals over 40 years of age with low-density lipoprotein (LDL) cholesterol levels greater than or equal to 130mg/dL.
Conditions Studied
Interventions
- DRUG DL-alpha-tocopherol
Study Locations (1)
California
- Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 1996-07 |
| Est. Completion | 2000-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114387
The ClinicalTrials.gov registry entry for NCT00114387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,061-participant average among 69 other Atherosclerosis trials with a reported enrollment target (67% lower). The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which DL-alpha-tocopherol is the first listed.
NCT00114387 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00114387 about?
NCT00114387 is a clinical study titled "VEAPS: Vitamin E Atherosclerosis Prevention Study". The purpose of this study is to examine whether vitamin E (DL-alpha-tocopherol) supplementation will reduce the progression of early atherosclerosis in healthy individuals over 40 years of age with low-density lipoprotein (LDL) cholesterol levels greater than or equal to 130mg/dL.
What is the current status of trial NCT00114387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 1996-07. Estimated completion is 2000-09.
What conditions does trial NCT00114387 study?
This clinical trial studies the following conditions: Atherosclerosis.
What interventions are being tested in trial NCT00114387?
The interventions under investigation include: DL-alpha-tocopherol (DRUG).
Who is sponsoring clinical trial NCT00114387?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114387 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Advancing Postmenopausal Preventive Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
COMPLETED · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.